U.S. FDA declines approval of pembrolizumab plus lenvatinib combination as first-line treatment for unresectable hepatocellular carcinoma

In a Complete Response Letter, the FDA did not consider the applications provided evidence that this regimen represents a meaningful advantage over available therapies. The companies said they plan to conduct a phase III trial (LEAP-002) to provide further evidence.


Biospace Inc.